# Pacira BioSciences Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-first-quarter-2026-financial-results
Ticker: PCRX
Company: Pacira BioSciences
Source: Pacira BioSciences
Published: 2026-04-30 20:01 EST
Original Source URL: https://investor.pacira.com
## Summary

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study

## Article Body
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study
## Recent Company News
- 2026-06-01 20:50 EST — [Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees](https://biopharmsignal.com/news/PCRX/pacira-biosciences-highlights-leading-independent-proxy-advisory-firm-iss-recommendation-to-vote-for-all-of-pacira-s-director-nominees) — Source: Pacira BioSciences
- 2026-05-28 20:20 EST — [Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees](https://biopharmsignal.com/news/PCRX/leading-independent-proxy-advisory-firm-glass-lewis-recommends-stockholders-vote-for-all-of-pacira-s-director-nominees) — Source: Pacira BioSciences
- 2026-05-27 20:20 EST — [Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees](https://biopharmsignal.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders-reiterating-confidence-in-the-company-s-strategic-direction-and-highly-qualified-nominees) — Source: Pacira BioSciences
- 2026-05-27 12:00 EST — [Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty](https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-real-world-study-showing-exparelr-use-was-associated-with-reduced-opioid-use-and-healthcare-costs-in-patients-undergoing-total-shoulder-arthroplasty) — Source: Pacira BioSciences
- 2026-05-26 12:00 EST — [Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy](https://biopharmsignal.com/news/PCRX/pacira-biosciences-sets-the-record-straight-regarding-doma-s-misleading-statements-about-pacira-s-intellectual-property-strategy) — Source: Pacira BioSciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)